Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to 9487.12%.

  • Ovid Therapeutics' EBIT Margin fell 18420300.0% to 9487.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 625.47%, marking a year-over-year decrease of 5944100.0%. This contributed to the annual value of 10933.75% for FY2024, which is 41889600.0% up from last year.
  • Latest data reveals that Ovid Therapeutics reported EBIT Margin of 9487.12% as of Q3 2025, which was down 18420300.0% from 80.88% recorded in Q2 2025.
  • In the past 5 years, Ovid Therapeutics' EBIT Margin registered a high of 84.73% during Q1 2021, and its lowest value of 115329.27% during Q3 2022.
  • Moreover, its 5-year median value for EBIT Margin was 9487.12% (2025), whereas its average is 14689.89%.
  • The largest annual percentage gain for Ovid Therapeutics' EBIT Margin in the last 5 years was 1042934900bps (2023), contrasted with its biggest fall of -207561800bps (2023).
  • Ovid Therapeutics' EBIT Margin (Quarter) stood at 11.92% in 2021, then soared by 54bps to 5.47% in 2022, then crashed by -49bps to 8.16% in 2023, then plummeted by -93551bps to 7645.09% in 2024, then dropped by -24bps to 9487.12% in 2025.
  • Its EBIT Margin stands at 9487.12% for Q3 2025, versus 80.88% for Q2 2025 and 9653.85% for Q1 2025.